IDP-023

N/A

Report date: 2025/02/21 16:20:22

Base Information

Drug NameIDP-023
Drug Alias NameIDP-023
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsHuman leukocyte antigen modulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsHuman leukocyte antigen
Therapy Area/IndicationsAutoimmune DiseasesImmune System DiseasesDemyelinating Diseases +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesIndapta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIndapta Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsMultiple MyelomaLymphoma, Non-Hodgkin
Inactive IndicationsAutoimmune DiseasesImmune System DiseasesDemyelinating Diseases +[7] 

Other Information

ATC CodeN/A
Related LinksN/A